What kind of company is zoetis?
What kind of company is zoetis?
animal health company
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years of experience, we deliver quality medicines and vaccines, complemented by diagnostic products and genetic tests and supported by a range of services.
Who is the CEO of zoetis?
Kristin C. Peck (Jan 1, 2020–)
Zoetis/CEO
Kristin Peck was appointed Chief Executive Officer of Zoetis in January 2020. In this role, she leads the world’s leading animal health company, a Fortune 500 organization with approximately $6 billion in annual revenue and 10,000 employees worldwide. Ms. Peck is also a member of the Zoetis Board of Directors.
When was Zoetis established?
1952
Zoetis/Founded
Who is Zoetis competitor?
Zoetis’ main competitors in the animal health market are German Boehringer Ingelheim, and U.S. -based Merck & Co. and Elanco (Eli Lilly).
What company owns Zoetis?
Pfizer
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world’s largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world’s largest drug maker, but with Pfizer’s spinoff of its 83% interest in the firm it is now a completely independent company.
What does Pfizer’s offer for Zoetis stock mean for shareholders?
The offer would allow Pfizer shareholders to exchange $100 worth of company stock for $107.52 worth of Zoetis stock. The premium is meant to encourage Pfizer shareholders to acquire Zoetis shares. Pfizer owns 400,985,000 shares of Zoetis Class B common stock that it will convert to Class A shares for the exchange.
Is Zoetis in the S&P 500?
Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index. In the 1950s, Pfizer began research on several drugs including Oxytetracycline.
What was the price of the Zoetis IPO?
Zoetis shares were priced at $26 in the February IPO and closed their first day of trading at $31.01. In April 2012 Pfizer sold its infant nutrition business to Nestle SA for $11.9 billion.
How many products does Zoetis have?
Overall, Zoetis has over 300 product lines on the market today, and it’s still growing. Much like Pfizer, Zoetis dominates its core markets, offering multiple brands that earn billions per year.
